Literature DB >> 22126871

Post-kala-azar dermal leishmaniasis: recent developments.

Sarman Singh1, Umakant Sharma, Jyotsna Mishra.   

Abstract

A substantial number of patients who recover from kala-azar will develop dermatosis [commonly known as post-kala-azar dermal leishmaniasis (PKDL)]. It usually occurs in the Indian subcontinent and East Africa. As many as 10-20% of Indian cases and 50-60% of Sudanese cases develop PKDL after successful treatment of visceral leishmaniasis. Most cases occur after infection with Leishmania donovani and less commonly after Leishmania infantum. However, the PKDL is extremely rare in patients infected with Leishmania chagasi. Though exact pathology is not yet fully known, here we review various evidence, which suggest that the pathogenesis is largely immunologically mediated. Our group has been of the opinion that PKDL disease manifestation is a result of in-vivo generation of quasi-species either as in-vivo hybridization of various circulating and latent populations of the causative species within the host cells or due to external reinfection. We, and other scientists, have recently demonstrated that strains of Leishmania that cause visceral diseases differ genetically from those that cause PKDL. We feel that this review will incite interest in several parasitologists and molecular biologists in the pathogenesis of this important manifestation of the infection, often blamed as the source of outbreaks of leishmaniasis.
© 2011 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2011        PMID: 22126871     DOI: 10.1111/j.1365-4632.2011.04925.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  18 in total

1.  Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.

Authors:  A C Vallur; A Hailu; D Mondal; C Reinhart; H Wondimu; Y Tutterrow; H W Ghalib; S G Reed; M S Duthie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-19       Impact factor: 3.267

Review 2.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

3.  Development of a Multiplexed Assay for Detection of Leishmania donovani and Leishmania infantum Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis.

Authors:  Claudia Abeijon; Fabiana Alves; Severine Monnerat; Monique Wasunna; Jane Mbui; Agostinho G Viana; Lilian L Bueno; Williane F Siqueira; Silvio G Carvalho; Neha Agrawal; Ricardo Fujiwara; Shyam Sundar; Antonio Campos-Neto
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 4.  Species typing in dermal leishmaniasis.

Authors:  Gert Van der Auwera; Jean-Claude Dujardin
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

6.  FIRST REPORT OF CUTANEOUS LEISHMANIASIS CAUSED BY Leishmania (Leishmania) infantum chagasi IN AN URBAN AREA OF RIO DE JANEIRO, BRAZIL.

Authors:  Marcelo Rosandiski Lyra; Maria Inês Fernandes Pimentel; Maria de Fátima Madeira; Liliane de Fátima Antonio; Janine Pontes de Miranda Lyra; Aline Fagundes; Armando de Oliveira Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Sep-Oct       Impact factor: 1.846

7.  Development and comparative evaluation of two antigen detection tests for Visceral Leishmaniasis.

Authors:  Aarthy C Vallur; Yeung L Tutterrow; Raodoh Mohamath; Sowmya Pattabhi; Asrat Hailu; Asim O Abdoun; Abdalla E Ahmed; Maowia Mukhtar; Md Abdus Salam; Meirielly Lima Almeida; Roque P Almeida; Dinesh Mondal; Audrey Albertini; Hashim Ghalib; Malcolm S Duthie; Steven G Reed
Journal:  BMC Infect Dis       Date:  2015-09-22       Impact factor: 3.090

8.  De Novo Whole-Genome Sequence and Annotation of a Leishmania Strain Isolated from a Case of Post-Kala-Azar Dermal Leishmaniasis.

Authors:  Anil Kumar Gupta; Saumya Srivastava; Amit Singh; Sarman Singh
Journal:  Genome Announc       Date:  2015-07-16

9.  Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Authors:  Sakib Burza; Prabhat Kumar Sinha; Raman Mahajan; Marta González Sanz; María Angeles Lima; Gaurab Mitra; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

10.  Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.

Authors:  A M Musa; E A G Khalil; B M Younis; M E E Elfaki; M Y Elamin; A O A Adam; H A A Mohamed; M M M Dafalla; A A Abuzaid; A M El-Hassan
Journal:  J Trop Med       Date:  2013-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.